Tag: Viaskin® Peanut

Viaskin Patch

Viaskin Peanut Completes Phase III Part A Study of Toddlers With...

Part B expected to commence in 2018Q4 with Viaskin Peanut 250 µg.
DBV Patch Closeup

Positive Safety Results Reported for Viaskin Peanut Phase III Trial

The trial met its primary objective, demonstrating that Viaskin Peanut was well-tolerated with no new or unexpected adverse events.

Viaskin Peanut Phase III Trial Falls Short, Still Chance for FDA...

The Viaskin Peanut patch therapy still has 50:50 chance of approval according to research note.
DBV Patch Closeup

DBV Completes Phase III Study of Peanut Patch

The phase III trial was designed to assess the safety and routine clinical use of Viaskin Peanut.
Viaskin Peanut

Peanut Patch Phase III Enrollment Ends, Results Expected Toward End of...

The study received higher-than-expected patient demand.
Packaged Foods

Study: Peanut Immunotherapy Significantly Reduces Risks Due to Cross-Contact in Common...

The study model used common packaged foods such as cookies, ice cream, and doughnuts as references.

Viaskin Peanut Patch: Lasting Response After Three Years

Pediatric patients responded with a favorable safety profile and no serious adverse effects.

Viaskin Patch Delivers Long-Lasting Peanut Desensitization After Phase IIb Trial

The study was designed to assess the long-term efficacy and safety of the treatment in subjects that had graduated from their earlier VIPES trial.

Peanut Patch Receives FDA’s Breakthrough Therapy Designation

The Viaskin Peanut patch received the BT designation after a positive Phase IIb trial.

Connect with Us

33,981FansLike
94FollowersFollow
140FollowersFollow
2,277FollowersFollow
5,120FollowersFollow
37SubscribersSubscribe